Search

Your search keyword '"Ghasemian Roya"' showing total 144 results
Start Over Author "Ghasemian Roya"
144 results on '"Ghasemian Roya"'

1. Serum and alveolar procalcitonin had a weak diagnostic value for ventilator-associated pneumonia in patients with pulmonary infection score ≥ 6

Author

Shokri Mehran, Ghasemian Roya, Bayani Masomeh, Maleh Parviz Amri, Kamrani Masoumeh, Sadeghi-Haddad-Zavareh Mahmoud, and Ebrahimpour Soheil

Subjects
alveolar procalcitonin, serum procalcitonin, ventilator-associated pneumonia, bronchoalveolar lavage, intensive care unit, Internal medicine, RC31-1245
Abstract

Background. Measuring the serum and alveolar procalcitonin level as inflammatory marker in the diagnosis of ventilator-associated pneumonia (VAP) has been taken into account. In this study, serum and alveolar procalcitonin levels in patients with suspected VAP and patients with confirmed VAP were compared.

Published
2018
Full Text
View/download PDF

2. Study of the Resistance of Escherichia Coli Which Creates Community-Acquired Urinary Tract Infections to Ciprofloxacin and Co-Trimoxazole Antibiotics in Sari Hospitals, Iran

Author

Ghasemian Roya, Shokri Mehran, Makhlough Atieh, and Fallah Mandana

Subjects
Antibiotic, Antimicrobial Resistance, Escherichia coli, Urinary Tract Infection, Medicine
Abstract

Objective: Escherichia coli is the most important etiologic factor in urinary tract infection (UTI), which is becoming resistant to the common antibiotics. The aim of this study was to evaluate the resistance of this bacterium to the antibiotics that are commonly used. Materials and Methods: A descriptive study conducted in patients with uncomplicated UTI referring to Sari hospitals during 2013-2014. For this purpose, samples that had positive urine culture were selected and evaluated with antibiogram. In addition, E-Test MIC method was used for antibiotics ciprofloxacin and co-trimoxazole. SPSS software was used for data analysis. Results: Of the 101 patients studied, 83 (82.2%) were females and 18 (17.8%) were male. The mean age of patients was 40.32 ± 3.22 years. The most sensitivity was seen to nitrofurantoin (92.07%), gentamicin (76.23%). Most resistance was also seen to the antibiotics amoxicillin (74.25%), co-trimoxazole (64.35%) and ciprofloxacin (36.63%). In E-Test MIC method, 23.7% were resistant to the ciprofloxacin and 43.5% to co-trimoxazole. Conclusion: Due to the high antibiotic resistance that was observed to ciprofloxacin and co-trimoxazole in this study, it seems a better alternative antibiotic such as nitrofurantoin should be used for the empirical treatment of patients with UTIs.

Published
2015

5. Evaluation of IFNAR2 and TYK2 transcripts’ prognostic role in COVID-19 patients: a retrospective study

Author

Razavi, Alireza, primary, Raei, Maedeh, additional, Hatami, Yasin, additional, Chokami, Ghazal Saghi, additional, Goudarzi, Yasaman, additional, Ghasemian, Roya, additional, Alizadeh-Navaei, Reza, additional, Yarmohammadi, Hossein, additional, Soltanipur, Masood, additional, Tabarestani, Mohammad, additional, Valadan, Reza, additional, Meshkinfam Haghighi, Faranak, additional, Tarsi, Abbas Khonakdar, additional, and Razavi, Bahar, additional

Published
2024
Full Text
View/download PDF

11. Efficacy and safety of adding fluoxetine to the treatment regimen of hospitalized patients with non‐critical COVID ‐19 pneumonia: A double‐blind randomized, placebo‐controlled clinical trial

Author

Sedighi, Faranak, primary, Zarghami, Mehran, additional, Alizadeh Arimi, Fatemeh, additional, Moosazadeh, Mahmood, additional, Ala, Shahram, additional, Ghasemian, Roya, additional, Mehravaran, Hossein, additional, and Elyasi, Forouzan, additional

Published
2023
Full Text
View/download PDF

12. IFI27 transcription is an early predictor for COVID-19 outcomes, a multi-cohort observational study

Author

Shojaei, Maryam, Shamshirian, Amir, Monkman, James, Grice, Laura, Tran, Minh, Tan, Chin Wee, Teo, Siok Min, Rodrigues Rossi, Gustavo, McCulloch, Timothy R., Nalos, Marek, Raei, Maedeh, Razavi, Alireza, Ghasemian, Roya, Gheibi, Mobina, Roozbeh, Fatemeh, Sly, Peter D., Spann, Kirsten M., Chew, Keng Yih, Zhu, Yanshan, Xia, Yao, Wells, Timothy J., Senegaglia, Alexandra Cristina, Kuniyoshi, Carmen Lúcia, Franck, Claudio Luciano, dos Santos, Anna Flavia Ribeiro, Noronha, Lucia de, Motamen, Sepideh, Valadan, Reza, Amjadi, Omolbanin, Gogna, Rajan, Madan, Esha, Alizadeh-Navaei, Reza, Lamperti, Liliana, Zuñiga, Felipe, Nova-Lamperti, Estefania, Labarca, Gonzalo, Knippenberg, Ben, Herwanto, Velma, Wang, Ya, Phu, Amy, Chew, Tracy, Kwan, Timothy, Kim, Karan, Teoh, Sally, Pelaia, Tiana M., Kuan, Win Sen, Jee, Yvette, Iredell, Jon, O’Byrne, Ken, Fraser, John F., Davis, Melissa J., Belz, Gabrielle T., Warkiani, Majid E., Gallo, Carlos Salomon, Souza-Fonseca-Guimaraes, Fernando, Nguyen, Quan, Mclean, Anthony, Kulasinghe, Arutha, Short, Kirsty R., Tang, Benjamin, Shojaei, Maryam, Shamshirian, Amir, Monkman, James, Grice, Laura, Tran, Minh, Tan, Chin Wee, Teo, Siok Min, Rodrigues Rossi, Gustavo, McCulloch, Timothy R., Nalos, Marek, Raei, Maedeh, Razavi, Alireza, Ghasemian, Roya, Gheibi, Mobina, Roozbeh, Fatemeh, Sly, Peter D., Spann, Kirsten M., Chew, Keng Yih, Zhu, Yanshan, Xia, Yao, Wells, Timothy J., Senegaglia, Alexandra Cristina, Kuniyoshi, Carmen Lúcia, Franck, Claudio Luciano, dos Santos, Anna Flavia Ribeiro, Noronha, Lucia de, Motamen, Sepideh, Valadan, Reza, Amjadi, Omolbanin, Gogna, Rajan, Madan, Esha, Alizadeh-Navaei, Reza, Lamperti, Liliana, Zuñiga, Felipe, Nova-Lamperti, Estefania, Labarca, Gonzalo, Knippenberg, Ben, Herwanto, Velma, Wang, Ya, Phu, Amy, Chew, Tracy, Kwan, Timothy, Kim, Karan, Teoh, Sally, Pelaia, Tiana M., Kuan, Win Sen, Jee, Yvette, Iredell, Jon, O’Byrne, Ken, Fraser, John F., Davis, Melissa J., Belz, Gabrielle T., Warkiani, Majid E., Gallo, Carlos Salomon, Souza-Fonseca-Guimaraes, Fernando, Nguyen, Quan, Mclean, Anthony, Kulasinghe, Arutha, Short, Kirsty R., and Tang, Benjamin

Abstract

Purpose: Robust biomarkers that predict disease outcomes amongst COVID-19 patients are necessary for both patient triage and resource prioritisation. Numerous candidate biomarkers have been proposed for COVID-19. However, at present, there is no consensus on the best diagnostic approach to predict outcomes in infected patients. Moreover, it is not clear whether such tools would apply to other potentially pandemic pathogens and therefore of use as stockpile for future pandemic preparedness. Methods: We conducted a multi-cohort observational study to investigate the biology and the prognostic role of interferon alpha-inducible protein 27 (IFI27) in COVID-19 patients. Results: We show that IFI27 is expressed in the respiratory tract of COVID-19 patients and elevated IFI27 expression in the lower respiratory tract is associated with the presence of a high viral load. We further demonstrate that the systemic host response, as measured by blood IFI27 expression, is associated with COVID-19 infection. For clinical outcome prediction (e.g., respiratory failure), IFI27 expression displays a high sensitivity (0.95) and specificity (0.83), outperforming other known predictors of COVID-19 outcomes. Furthermore, IFI27 is upregulated in the blood of infected patients in response to other respiratory viruses. For example, in the pandemic H1N1/09 influenza virus infection, IFI27-like genes were highly upregulated in the blood samples of severely infected patients. Conclusion: These data suggest that prognostic biomarkers targeting the family of IFI27 genes could potentially supplement conventional diagnostic tools in future virus pandemics, independent of whether such pandemics are caused by a coronavirus, an influenza virus or another as yet-to-be discovered respiratory virus.

Published
2023

13. Helicobacter pylori Infection and Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis

Author

Heydari, Keyvan, Yousefi, Mohammad, Alizadeh-Navaei, Reza, Lotfi, Parisa, Sheydaee, Fateme, Raei, Maedeh, Vahdatinia, Alireza, Hessami, Amirhossein, Rafati, Sajjad, Moosazadeh, Mahmood, Ghasemian, Roya, Salehi, Fatemeh, Massoudi, Haleh, Ghaffari-Saravi, Fatemeh, and Rismantab, Sahar

Subjects
Cross-Sectional Studies, Helicobacter pylori, Non-alcoholic Fatty Liver Disease, Risk Factors, Odds Ratio, Humans, Review, Helicobacter Infections
Abstract

Since numerous studies have stated that there may be a relationship between Helicobacter pylori infection and nonalcoholic fatty liver disease, and because of the high prevalence of both conditions worldwide, this study investigated the risk of non-alcoholic fatty liver disease in patients infected with H. pylori. Following a systematic review of PubMed, Scopus, Web of Science and Embase, and a search in Google Scholar using MeSH terms such as H. pylori and non-alcoholic fatty liver disease, the relevant papers up to November 2020 were reviewed. All cohort, case-control, and cross-sectional studies that examined the risk of developing non-alcoholic fatty liver disease in patients infected with H. pylori entered this study. A meta-analysis was conducted in STATA 11. This systematic review examined 22 papers with 117 117 participants (33 711 patients infected with H. pylori and 83 406 participants as control) and 20 studies were subjected to meta-analysis The results indicated a 22% to 27% increase in the risk of developing non-alcoholic fatty liver disease in patients infected with H. pylori (crude odds ratio: 1.27, 95% CI: 1.17-1.33; and adjusted odds ratio: 1.22, 95% CI: 1.09-1.35). According to the subgroup analysis, the study region, sample size, and the method of diagnosing H. pylori were the factors contributing to the high heterogeneity. The meta-analysis revealed the increased risk of developing non-alcoholic fatty liver disease in patients infected with H. pylori. This indicates that H. pylori is a serious risk factor in patients susceptible to NAFLD.

Published
2022
Full Text
View/download PDF

14. IFI27 transcription is an early predictor for COVID-19 outcomes, a multi-cohort observational study

Author

Shojaei, Maryam, primary, Shamshirian, Amir, additional, Monkman, James, additional, Grice, Laura, additional, Tran, Minh, additional, Tan, Chin Wee, additional, Teo, Siok Min, additional, Rodrigues Rossi, Gustavo, additional, McCulloch, Timothy R., additional, Nalos, Marek, additional, Raei, Maedeh, additional, Razavi, Alireza, additional, Ghasemian, Roya, additional, Gheibi, Mobina, additional, Roozbeh, Fatemeh, additional, Sly, Peter D., additional, Spann, Kirsten M., additional, Chew, Keng Yih, additional, Zhu, Yanshan, additional, Xia, Yao, additional, Wells, Timothy J., additional, Senegaglia, Alexandra Cristina, additional, Kuniyoshi, Carmen Lúcia, additional, Franck, Claudio Luciano, additional, dos Santos, Anna Flavia Ribeiro, additional, Noronha, Lucia de, additional, Motamen, Sepideh, additional, Valadan, Reza, additional, Amjadi, Omolbanin, additional, Gogna, Rajan, additional, Madan, Esha, additional, Alizadeh-Navaei, Reza, additional, Lamperti, Liliana, additional, Zuñiga, Felipe, additional, Nova-Lamperti, Estefania, additional, Labarca, Gonzalo, additional, Knippenberg, Ben, additional, Herwanto, Velma, additional, Wang, Ya, additional, Phu, Amy, additional, Chew, Tracy, additional, Kwan, Timothy, additional, Kim, Karan, additional, Teoh, Sally, additional, Pelaia, Tiana M., additional, Kuan, Win Sen, additional, Jee, Yvette, additional, Iredell, Jon, additional, O’Byrne, Ken, additional, Fraser, John F., additional, Davis, Melissa J., additional, Belz, Gabrielle T., additional, Warkiani, Majid E., additional, Gallo, Carlos Salomon, additional, Souza-Fonseca-Guimaraes, Fernando, additional, Nguyen, Quan, additional, Mclean, Anthony, additional, Kulasinghe, Arutha, additional, Short, Kirsty R., additional, and Tang, Benjamin, additional

Published
2023
Full Text
View/download PDF

16. Non-effectiveness of Ivermectin on Inpatients and Outpatients With COVID-19; Results of Two Randomized, Double-Blinded, Placebo-Controlled Clinical Trials

Author

Rezai, Mohammad Sadegh, primary, Ahangarkani, Fatemeh, additional, Hill, Andrew, additional, Ellis, Leah, additional, Mirchandani, Manya, additional, Davoudi, Alireza, additional, Eslami, Gohar, additional, Roozbeh, Fatemeh, additional, Babamahmoodi, Farhang, additional, Rouhani, Nima, additional, Alikhani, Ahmad, additional, Najafi, Narges, additional, Ghasemian, Roya, additional, Mehravaran, Hossein, additional, Hajialibeig, Azin, additional, Navaeifar, Mohammad Reza, additional, Shahbaznejad, Leila, additional, Rahimzadeh, Golnar, additional, Saeedi, Majid, additional, Alizadeh-Navai, Reza, additional, Moosazadeh, Mahmood, additional, Saeedi, Shahab, additional, Razavi-Amoli, Seyedeh-Kiana, additional, Rezai, Shaghayegh, additional, Rostami-Maskopaee, Fereshteh, additional, Hosseinzadeh, Fatemeh, additional, Movahedi, Faezeh Sadat, additional, Markowitz, John S., additional, and Valadan, Reza, additional

Published
2022
Full Text
View/download PDF

17. Fatal Prosthetic Valve Endocarditis Due to Aspergillus flavus in a Diabetic Patient

Author

Jalalian, Rozita, Shokohi, Tahereh, Mirzakhani, Roghayeh, Ghasemian, Roya, Hedayati, Mohammad Taghi, Ardalani, Sirus, Azizi, Soheil, Kalhori, Shamsi, Kermani, Firoozeh, and Mayahi, Sabah

Subjects
Aspergillus, prosthetic valve replacement, fungal endocarditis, Case Report, antifungal
Abstract

Aspergillus endocarditis (AE) accounts for a-quarter of all fungal endocarditis, mainly in immunocompromised hosts prior to heart-valve surgery with high mortality, even with treatment. Herein, we report a rare case of AE in a diabetic 60-year-old woman with a history of redo mitral valve prosthesis suspecious of acute endocarditis. She underwent second redo surgical mitral valve replacement in combination with mechanical aortic valve replacement. Blood cultures were negative. The explanted valve and vegetation were subjected to identification. Grown colonies were identified as Aspergillus flavus, based on conventional and molecular methods. Despite the administration of liposomal amphotericin B and improvement in her general condition shortly after initiation of therapy, the patient passed away. As AE is a late consequence of redo prosthetic valve replacement, extended follow-up, early diagnosis, repeating valve-replacement surgeries, and timely selective antifungal treatments are warranted.

Published
2020

20. The role of vitamin D in the age of COVID‐19: A systematic review and meta‐analysis

Author

Ghasemian, Roya, primary, Shamshirian, Amir, additional, Heydari, Keyvan, additional, Malekan, Mohammad, additional, Alizadeh‐Navaei, Reza, additional, Ebrahimzadeh, Mohammad Ali, additional, Ebrahimi Warkiani, Majid, additional, Jafarpour, Hamed, additional, Razavi Bazaz, Sajad, additional, Rezaei Shahmirzadi, Arash, additional, Khodabandeh, Mehrdad, additional, Seyfari, Benyamin, additional, Motamedzadeh, Alireza, additional, Dadgostar, Ehsan, additional, Aalinezhad, Marzieh, additional, Sedaghat, Meghdad, additional, Razzaghi, Nazanin, additional, Zarandi, Bahman, additional, Asadi, Anahita, additional, Yaghoubi Naei, Vahid, additional, Beheshti, Reza, additional, Hessami, Amirhossein, additional, Azizi, Soheil, additional, Mohseni, Ali Reza, additional, and Shamshirian, Danial, additional

Published
2021
Full Text
View/download PDF

23. Clinical Effectiveness of a High Dose Versus the Standard Dose of Meropenem in Ventilator-associated Pneumonia Caused by Multidrugresistant Bacteria: A Randomized, Single-blind Clinical Trial

Author

Monajati, Mahila, primary, Ala, Shahram, additional, Aliyali, Masoud, additional, Ghasemian, Roya, additional, Heidari, Fatemeh, additional, Ahanjan, Mohammad, additional, Moradi, Siavash, additional, Sharifpour, Ali, additional, Mojtahedzadeh, Mojtaba, additional, and Salehifar, Ebrahim, additional

Published
2021
Full Text
View/download PDF

25. Hydroxychloroquine Versus COVID-19: A Periodic Systematic Review and Meta-Analysis

Author

Shamshirian, Amir, Hessami, Amirhossein, Heydari, Keyvan, Alizadeh-Navaei, Reza, Ebrahimzadeh, Mohammad Ali, YIP, George W, Ghasemian, Roya, Behnamfar, Morteza, Baradaran, Hananeh, Aboufazeli, Elham, Jafarpour, Hamed, Karimifar, Keyvan, Eftekhari, Aida, and Shamshirian, Danial

Abstract

Importance: This systematic review and meta-analysis not only indicated no clinical benefits regarding hydroxychloroquine (HCQ) treatment with/without azithromycin for COVID-19 patients, but the higher mortality rate and frequency of known HCQ adverse effects were observed for the HCQ/HCQ+AZM regimen group. Objective: To overcome the controversies regarding the effectiveness of hydroxychloroquine in the treatment of COVID-19 through meta-analysis. Data Sources: A systematic search was performed in PubMed, Scopus, Embase, Cochrane Library, Web of Science, Google Scholar and medRxiv pre-print database using all available MeSH terms for COVID-19 and hydroxychloroquine up to May 14, 2020. Study Selection: Studies focused on the effectiveness of HCQ with/without azithromycin (AZM) in confirmed COVID-19 patients were entered into the study including: comparative or non-comparative clinical studies including observational/interventional studies with retrospective/prospective nature with/without control group as well as Randomized Clinical Trials (RCTs). Data Extraction and Synthesis: Two researchers have independently evaluated quality assessment of the studies and abstracted data for data extraction, which has reviewed by the supervisor for accuracy. Extracted data were analyzed using CMA v. 2.2.064. Heterogeneity was assessed using the I-squared (I2) test, and fixed/random-effects model was used when appropriate for pooling of studies. Main Outcome(s) and Measure(s): 1) Clinical effectiveness of HCQ with/without AZM in the treatment of COVID-19; 2) Mortality rate; 3) Disease exacerbation; 4) Frequency of known HCQ adverse effects occurred during treatment; 5) Intubation need; 6) Radiological improvement. Results: Out of 21 studies entered into our systematic review, 18 studies including 11 comparative studies with control group and seven observational studies containing 5,561 participants have entered into the study. The results of the meta-analysis on comparative studies indicated no significant clinical effectiveness (negative in RT-PCR evaluation) for HCQ regimen in the treatment of COVID-19 in comparison to control group (RR: 0.96, 95% CI, 0.76-1.22). The same result was observed for the combination of HCQ+azithromycin (RR: 2.15, 95% CI, 0.31-14.77). Approximately 1.5 times higher mortality rate was observed among the HCQ regimen group (RR: 1.54, 95% CI, 1.04-2.29) and 3.5 times higher in HCQ+AZM (RR: 3.65, 95% CI, 1.10-12.10) group in comparison to control group, which was affected by age differences according to meta-regression analysis (P=0.0003). No substantial difference was observed for disease exacerbation (RR: 1.60, 95% CI, 0.54-4.71) between HCQ group and controls. Also, radiological findings significantly improved in the HCQ group (OR: 0.32, 95% CI, 0.11-0.98). Odds of known HCQ adverse effects (diarrhea, vomiting, blurred vision, rash, headache, etc.) occurred in the HCQ regimen group was approximately 3.5 times of control group (OR: 3.55, 95% CI, 1.61-7.82), but no substantial differences were found regarding intubation odds between HCQ group and control group (OR: 2.11, 95% CI, 0.31-14.03). Conclusions and Relevance: This systematic review and meta-analysis not only showed no clinical benefits regarding HCQ treatment with/without azithromycin for COVID-19 patients, but according to multiple sensitivity analysis, the higher mortality rates were observed for both HCQ and HCQ+AZM regimen groups, especially in the latter. Also, frequency of adverse effects was higher in HCQ regimen group. However, due to that most of the studies were non-randomized and results were not homogenous, selection bias was unavoidable and further large randomized clinical trials following comprehensive meta-analysis should be taken into account in order to achieve more reliable findings.

Published
2020
Full Text
View/download PDF

26. Fatal Prosthetic Valve Endocarditis Due to Aspergillus flavus in a Diabetic Patient

Author

Jalalian,Rozita, Shokohi,Tahereh, Mirzakhani,Roghayeh, Ghasemian,Roya, Hedayati,Mohammad Taghi, Ardalani,Siros, Azizi,Soheil, Kalhori,Shamsi, Kermani,Firoozeh, Mayahi,Sabah, Jalalian,Rozita, Shokohi,Tahereh, Mirzakhani,Roghayeh, Ghasemian,Roya, Hedayati,Mohammad Taghi, Ardalani,Siros, Azizi,Soheil, Kalhori,Shamsi, Kermani,Firoozeh, and Mayahi,Sabah

Abstract

Rozita Jalalian,1 Tahereh Shokohi,2,3 Roghayeh Mirzakhani,4 Roya Ghasemian,5 Mohammad Taghi Hedayati,2,3 Sirus Ardalani,6 Soheil Azizi,7 Shamsi Kalhori,7 Firoozeh Kermani,4 Sabah Mayahi3 1Department of Cardiology, Mazandaran University of Medical Sciences, Sari, Iran; 2Invasive Fungi Research Centre (IFRC), Mazandaran University of Medical Sciences, Sari, Iran; 3Department of Medical Mycology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran; 4Student Research Committee, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran; 5Antimicrobial Resistance Research Center, and Department of Infectious Diseases, Mazandaran University of Medical Sciences, Sari, Iran; 6Department of Cardiac Surgery, Cardiovascular Research Center of Mazandaran Heart Center, Mazandaran University of Medical Sciences, Sari, Iran; 7Department of Pathology, Mazandaran Heart Center, Mazandaran University of Medical Sciences, Sari, IranCorrespondence: Tahereh ShokohiDepartment of Medical Mycology, School of Medicine, Mazandaran University of Medical Sciences, Sari, IranTel +98 11 3354-3087Fax +98 11 3354-3248Email Shokohi.tahereh@gmail.comAbstract: Aspergillus endocarditis (AE) accounts for a-quarter of all fungal endocarditis, mainly in immunocompromised hosts prior to heart-valve surgery with high mortality, even with treatment. Herein, we report a rare case of AE in a diabetic 60-year-old woman with a history of redo mitral valve prosthesis suspecious of acute endocarditis. She underwent second redo surgical mitral valve replacement in combination with mechanical aortic valve replacement. Blood cultures were negative. The explanted valve and vegetation were subjected to identification. Grown colonies were identified as Aspergillus flavus, based on conventional and molecular methods. Despite the administration of liposomal amphotericin B and improvement in her general condition shortly after initiation of therapy, the patient passed away. As AE is a l

Published
2020

29. Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective open-label uncontrolled multicenter trial

Author

Malekzadeh, Reza, primary, Abedini, Atefeh, additional, Mohsenpour, Behzad, additional, Sharifipour, Ehsan, additional, Ghasemian, Roya, additional, Javad-Mousavi, Seyed Ali, additional, Khodashahi, Rozita, additional, Darban, Mahboobeh, additional, Kalantari, Saeed, additional, Abdollahi, Nafiseh, additional, Salehi, Mohammad Reza, additional, Rezaei Hosseinabadi, Abbas, additional, Khorvash, Farzin, additional, Valizadeh, Melika, additional, Dastan, Farzaneh, additional, Yousefian, Sahar, additional, Hosseini, Hamed, additional, Anjidani, Nassim, additional, and Tabarsi, Payam, additional

Published
2020
Full Text
View/download PDF

30. The Role of Hydroxychloroquine in COVID-19 Treatment: A Systematic Review and Meta-Analysis

Author

Shamshirian, Amir, primary, Hessami, Amirhossein, additional, Heydari, Keyvan, additional, Alizadeh-Navaei, Reza, additional, Ebrahimzadeh, Mohammad Ali, additional, Yip, George W, additional, Ghasemian, Roya, additional, Sedaghat, Meghdad, additional, Baradaran, Hananeh, additional, Mohammadi Yazdii, Soheil, additional, Aboufazeli, Elham, additional, Jafarpour, Hamed, additional, Dadgostar, Ehsan, additional, Tirandazi, Behnaz, additional, Sadeghnezhad, Reza, additional, Karimifar, Keyvan, additional, Eftekhari, Aida, additional, and Shamshirian, Danial, additional

Published
2020
Full Text
View/download PDF

31. Apoptosis and immunophenotyping of peripheral blood lymphocytes in Iranian COVID‐19 patients: Clinical and laboratory characteristics

Author

Taghiloo, Saeid, primary, Aliyali, Masoud, additional, Abedi, Siavash, additional, Mehravaran, Hossein, additional, Sharifpour, Ali, additional, Zaboli, Ehsan, additional, Eslami‐Jouybari, Mohammad, additional, Ghasemian, Roya, additional, Vahedi‐Larijani, Laleh, additional, Hossein‐Nattaj, Hadi, additional, Amjadi, Omolbanin, additional, Rezazadeh, Hadiseh, additional, Ajami, Abolghasem, additional, and Asgarian‐Omran, Hossein, additional

Published
2020
Full Text
View/download PDF

34. The Role of Vitamin D in the Age of COVID-19: A Systematic Review and Meta-Analysis

Author

Ghasemian, Roya, primary, Shamshirian, Amir, additional, Heydari, Keyvan, additional, Malekan, Mohammad, additional, Alizadeh-Navaei, Reza, additional, Ebrahimzadeh, Mohammad Ali, additional, Jafarpour, Hamed, additional, Shahmirzadi, Arash Rezaei, additional, Khodabandeh, Mehrdad, additional, Seyfari, Benyamin, additional, Motamedzadeh, Alireza, additional, Dadgostar, Ehsan, additional, Aalinezhad, Marzieh, additional, Sedaghat, Meghdad, additional, Razzaghi, Nazanin, additional, Zarandi, Bahman, additional, Asadi, Anahita, additional, Naei, Vahid Yaghoubi, additional, Beheshti, Reza, additional, Hessami, Amirhossein, additional, Azizi, Soheil, additional, Mohseni, Ali Reza, additional, and Shamshirian, Danial, additional

Published
2020
Full Text
View/download PDF

37. The Role of Hydroxychloroquine in the Age of COVID-19: A Periodic Systematic Review and Meta-Analysis

Author

Shamshirian, Amir, primary, Hessami, Amirhossein, additional, Heydari, Keyvan, additional, Alizadeh-Navaei, Reza, additional, Ebrahimzadeh, Mohammad Ali, additional, Yip, George W., additional, Ghasemian, Roya, additional, Sedaghat, Meghdad, additional, Baradaran, Hananeh, additional, Yazdi, Soheil Mohammadi, additional, Aboufazeli, Elham, additional, Jafarpour, Hamed, additional, Dadgostar, Ehsan, additional, Tirandazi, Behnaz, additional, Karimifar, Keyvan, additional, Eftekhari, Aida, additional, and Shamshirian, Danial, additional

Published
2020
Full Text
View/download PDF

39. Atazanavir versus lopinavir on Covid-19 infection: A retrospective protease inhibitors comparative study 2020.

Author

Alikhani, Ahmad, Ghazaiean, Mobin, Ghasemian, Roya, and Khademloo, Mohammad

Subjects
COVID-19, PROTEASE inhibitors, ATAZANAVIR, LIVER function tests, LOPINAVIR-ritonavir
Abstract

Background: Evaluation of protease inhibitors (PIs) is important in terms of prescribing an effective regimen for reducing mortality and hospitalization in Covid-19. Therefore, followup of patients better determines the characteristics of existing regimens. Methods: We retrospectively evaluated the demographic, co-morbidities, gastrointestinal (GI) and liver complications of patients at two teaching hospitals from the first of March to the end of July 2020. All patients received one of two recommended regimens including hydroxychloroquine (HCQ) (400 mg BD on the first day and then 200 mg BD) plus atazanavir/ritonavir (ATV) (300/100 mg daily) or HCQ with the same dose plus lopinavir/ritonavir (Kaletra) (400/100 mg BD) for 5-7 days. Results: We chose 170 cases that received 2 different regimens. In group one, 85(57.6% males) patients received Kaletra and HCQ and group two, 85 (55.3% males) patients received ATV and HCQ. The study of hospitalization in both groups showed no difference in more or less than 5 days hospitalization. (P=0.757) Comparison of mortality rates has not shown a significant difference including 19 (22.4%) deaths in group 1 and 15(17.6%) deaths in group 2 (P=0.443). Nausea followed by diarrhea was the most common side effects in group 1. But no side effects were reported in group 2 (P=0.000). Abnormal liver function tests (LFTs) were seen in both groups. Conclusion: Comparison of hospitalization and mortality were not statistically significant. It seems that a respect to similar effect on mortality and hospitalization. ATV regimen is superior to Kaletra especially for better GI tolerance and less daily pills. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

41. Immunologic markers, vasculitis-associated autoantibodies, and complement levels in patients with COVID-19.

Author

Mobini, Maryam, Ghasemian, Roya, Larijani, Laleh Vahedi, Mataji, Maede, and Maleki, Iradj

Subjects
*AUTOANTIBODIES, *BIOMARKERS, *COVID-19, *COMPLEMENT (Immunology), *RNA-binding proteins, *SEVERITY of illness index, *FLUORESCENT antibody technique, *VASCULITIS, *SYMPTOMS
Abstract

Background: The cause of coronavirus disease 2019 (COVID-19) is a virus which can lead to severe acute respiratory syndrome-CoV-2 (SARS-COV-2). There are evidences of involvement of immune system in pathogenesis of this disease. We investigated the presence of various vasculitis-associated autoantibodies and complement levels in patients with COVID-19. Materials and Methods: Patients with severe or critical type of COVID-19 were evaluated for symptoms, signs, and laboratory tests of vasculitis syndromes including rheumatoid factor (RF), antinuclear antibody (ANA), anti-double-stranded DNA, c and p anti-neutrophilic cytoplasmic antibody (c ANCA and P ANCA), and complement levels. Results: The study was performed in forty patients with severe or critical illness. The mean age of the participants was 48.5 ± 9.8 years. All patients had pulmonary involvement in lung computed tomography scans. Vasculitis laboratory test results included RF in two patients, ANA in three patients, and ANCA in one patient. Seventeen (42.5%) patients had hypocomplementemia in one or more complement tests. Four patients expired, of whom three had a decrease in complement level. Conclusion: Decrease in complement levels may predict a critical state of COVID-19 disease. Therefore, measuring its levels may be of great benefit in making earlier decisions to initiate disease-suppressing treatments including corticosteroids. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

42. Apoptosis and immunophenotyping of peripheral blood lymphocytes in Iranian COVID‐19 patients: Clinical and laboratory characteristics.

Author

Taghiloo, Saeid, Aliyali, Masoud, Abedi, Siavash, Mehravaran, Hossein, Sharifpour, Ali, Zaboli, Ehsan, Eslami‐Jouybari, Mohammad, Ghasemian, Roya, Vahedi‐Larijani, Laleh, Hossein‐Nattaj, Hadi, Amjadi, Omolbanin, Rezazadeh, Hadiseh, Ajami, Abolghasem, and Asgarian‐Omran, Hossein

Subjects
SARS-CoV-2, LYMPHOCYTE subsets, IRANIANS, LYMPHOCYTES, COVID-19
Abstract

A novel member of human coronavirus, named severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2), has been recently recognized in China and rapidly spread worldwide. Studies showed the decreasing of peripheral blood lymphocytes in a majority of patients. In this study, we have reported the clinical features, laboratory characteristics, the frequency of peripheral blood lymphocyte subpopulations, and their apoptosis pattern in Iranian coronavirus infectious disease (COVID‐19) patients. Demographic and clinical data of 61 hospitalized confirmed cases with COVID‐19 at Imam Khomeini Hospital were collected and analyzed. Peripheral blood mononuclear cells were isolated from all samples and the apoptosis pattern was evaluated using Annexin V/propidium iodide method. The frequency of lymphocyte subsets, including T‐CD4+, T‐CD8+, NK, B cells, and monocytes, was measured in all patients and 31 controls by flow cytometry. Our findings demonstrated that the percentage of lymphocytes, CD4+, and CD8+ T cells were decreased in COVID‐19 patients compared with the control group. Regarding the clinical severity, the number of lymphocytes, CD4+, CD8+ T cells, and NK cells were also decreased in severe cases when compared with mild cases. Finally, our data have also indicated the increase in apoptosis of mononuclear cells from COVID‐19 patients which was more remarkable in severe clinical cases. The frequency of immune cells is a useful indicator for prediction of severity and prognosis of COVID‐19 patients. These results could help to explain the immunopathogenesis of SARS‐CoV‐2 and introducing novel biomarkers, therapeutic strategies, and vaccine candidates. Highlights: The percentage of lymphocytes, CD4+, and CD8+ T cells were decreased in COVID‐19 patients compared to control group. Regarding the clinical severity, the number of lymphocytes, CD4+, CD8+ T cells, and NK cells were also decreased in severe cases when compared to mild cases. Our data have indicated the increasing in apoptosis of mononuclear cells from COVID‐19 patients which was more remarkable in severe clinical cases. The frequency of immune cells is a useful indicator for prediction of severity and prognosis of COVID‐19 patients. These results could help to explain the immunopathogenesis of SARS‐CoV‐2 and introducing of novel biomarkers, therapeutic strategies, and vaccine candidates. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

43. Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in COVID-19 Patients and Control Group and Relationship with Disease Prognosis.

Author

Eslamijouybari, Mohammad, Heydari, Keyvan, Maleki, Iradj, Moosazadeh, Mahmood, Hedayatizadeh-Omran, Akbar, Vahedi, Lale, Ghasemian, Roya, Sharifpour, Ali, and Alizadeh-Navaei, Reza

Subjects
COVID-19, PROGNOSIS, PLATELET count, LYMPHOCYTE count, CONTROL groups
Abstract

Background: The present study aimed to compare the complete blood count (CBC) indices between COVID-19 patients and the control group, and assess the relationship of these indices with COVID-19 prognosis. Methods: COVID-19 patients (confirmed by PCR or CT-Scan) who visited Imam Hospital in Sari were selected in this case-control study. The control group was selected from Tabari cohort population matched with the case group in terms of gender and age. CBC, neutrophilto- lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and outcome of the disease (in the case group) were assessed in this study. Results: The number of participants were 527 in both case and control groups, of which, 232 (44%) were females in each arms. Platelet count, lymphocyte count, and hemoglobin concentration were also higher in the control group (P=0.000). NLR and PLR were significantly higher in COVID-19 patients compared to the control group (P=0.000). NLR had a significant relationship with the severity of the disease. NLR was two times higher in the patients who died of COVID-19 than those who recovered (P=0.000). ROC curve analysis for diagnostic values of NLR and PLR showed that the areas under the ROC curves for NLR and PLR were 0.703 (95% CI: 0.64-0.76) and 0.535 (95% CI: 0.46-06), respectively. Conclusion: NLR can be used as a prognostic marker for COVID-19 given the significant difference of NLR between those who died and recovered from COVID-19. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

49. Efficacy and Safety of a Protein-Based SARS-CoV-2 Vaccine: A Randomized Clinical Trial.

Author

Mostafavi, Ehsan, Eybpoosh, Sana, Karamouzian, Mohammad, Khalili, Malahat, Haji-Maghsoudi, Saiedeh, Salehi-Vaziri, Mostafa, Khamesipour, Ali, Jalali, Tahmineh, Nakhaeizadeh, Mehran, Sharifi, Hamid, Mansoori, Yasaman, Keramat, Fariba, Ghodrati, Samad, Javanian, Mostafa, Doroud, Delaram, Omrani, Mir Davood, Asadi, Hassan, Pouriayevali, Mohammad Hassan, Ghasemian, Roya, and Farshidi, Hossein

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results